Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazoprevir/Elbasvir in Post-Transplant Genotype 1b HCV
NCT03723824Phase 4Terminated
- Sponsor
- Taichung Veterans General Hospital
- Start
- Feb 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of grazoprevir in hepatitis C (HCV), sponsored by Taichung Veterans General Hospital. Primary endpoint: Sustained Virologic Response. Started Feb 2019; status: terminated.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03723824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03723824.